Therefore, it can be speculated that the most common smoking‐related mutation in lung adenocarcinoma, KRAS, can be used as an effective predictor of anti‐PD‐1/PD‐L1 immunotherapy. This evidence concerns the gene KRAS and lung adenocarcinoma.